A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Sign Up to like & getrecommendations! Published in 2020 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2020.07.072
Abstract: Cancer immunotherapy have changed the paradigm of cancer treatment, but there remains a great need for improvement given that less patients with tumors respond to the treatment of PD-1/PD-L1 blockade. TIGIT (also called T cell… read more here.
Keywords: immune checkpoint; tigit; blockade; cell ... See more keywords
Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003655
Abstract: T cell-based immunotherapy, for example, with T cell-recruiting bispecific antibody (bsAb), has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions are still rare. Several tumor immune evasion mechanisms have… read more here.
Keywords: cell; recruiting bispecific; bsab; treatment ... See more keywords
Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Sign Up to like & getrecommendations! Published in 2018 at "Protein and peptide letters"
DOI: 10.2174/0929866524666171017143753
Abstract: BACKGROUND Bispecific antibodies, BsAbs, are molecules with the ability to bind to two different epitopes on the same or different antigens. c-MET, cellular-mesenchymal to epithelial transition factor, is deregulated in many types of human malignancies.… read more here.
Keywords: targeting met; antibody targeting; tumor cells; bispecific antibody ... See more keywords
The combination therapy with EpCAM/CD3 BsAb and MUC-1/CD3 BsAb elicited antitumor immunity by T-cell adoptive immunotherapy in lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Medical Sciences"
DOI: 10.7150/ijms.61681
Abstract: Lung cancer remains a global challenge due to high morbidity and mortality rates and poor response to treatment, and there are still no effective strategies to solve it. The bispecific antibody (BsAb) is a novel… read more here.
Keywords: cd3 bsab; lung cancer; bsab;